biotechnology-2018-keynote

6 / 6

Volume 2 Journal of Medical Biotechnology Biotechnology 2018
July 16-17, 2018
Page 17
Notes:
World Biotechnology Congress
July 16-17, 2018 Berlin, Germany
Joel I Osorio, J Med Biotechnol 2018, Volume 2
RegenerAge system: Therapeutic effects of combinatorial biologics (mRNA and allogenic MSCs) with a
spinal cord stimulation system on a patient with spinal cord section
As it has been previously demonstrated that co-electroporation of Xenopus laevis frog oocytes with normal cells and
cancerous cell lines induces the expression of pluripotency markers and in experimental murine model studies that
mRNA extract (Bioquantine®) purified from intra and extra-oocyte liquid phases of electroporated oocytes) showed potential
as a treatment for a wide range of conditions, including Spinal Cord Injury (SCI) among others. The current study observed
beneficial changes with Bioquantine® administration in a patient with severe SCI. Pluripotent stem cells have therapeutic and
regenerative potential in clinical situations CNS disorders even cancer. One method of reprogramming somatic cells into
pluripotent stem cells is to expose them to extracts prepared from Xenopus laevis oocytes. The positive human findings for
spinal cord injury with the results from previous animal studies with experimental models of traumatic brain injury and SCI,
respectively as our evidence and due to ethical reasons, legal restrictions and a limited number of patients, we were able to treat
only a very small number of patients, deciding to include in our protocol the RestoreSensor SureScan to complete it. Based
on the electrical stimulation for rehabilitation and regeneration after spinal cord injury published by Hamid and MacEwan,
we designed an improved delivery method for the in situ application of MSCs and Bioquantine® in combination with the
RestoreSensor® SureScan®. To the present day the patient who suffered a complete section of spinal cord at T12-L1 shows an
improvement in sensitivity, strength in striated muscle and smooth muscle connection, 13 months after the first treatment
and 6 months after the placement of RestoreSensor® at the level of the lesion, showing an evident improvement on his therapy
of physical rehabilitation (legs movement) on crawling forward and backwards and standing on his feet for the first time and
showing a progressively important functionality on both limbs.
Biography
Joel L osorio is the CEO and Founder of Biotechnology and Regenerative Medicine at RegenerAge International ™ H Vice President of International Clinical Development
for Bioquark, Inc. and Chief Clinical Officer at ReAnima™ Advanced Biosciences . Advance Fellow by the American Board of Anti-Aging and Regenerative Medicine
(A4M), Visiting Scholar at University of North Carolina at Chapel Hill (Dermatology). Fellow in Stem Cell Medicine by the American Academy of Anti-Aging Medicine and
University of South Florida
Joel I Osorio
RegenerAge International, USA